Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Feb 12, 2018 3:11pm

126 Views

Post# 27546362

RE:RE:RE:HOPE THIS DOES NOT HAPPEN TO RVX

Jkj, it is scary because generally we don't have control and the big guys take advantage.

I don't think this will happen with RVX but I am concerned that they are being pushed into a corner and at that stage anything can happen.

I'd just love to see this little Calgary success story be rewarded for what I think their processes, scaffolds, the BoM apabetalone trial, the 2500 other compounds, etc have achieved.

Cheers
Toinv

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market